Stocks to sell

Renewable energy trends may bode well for Bloom Energy (NYSE:BE) in theory, but as you can see from any BE stock chart, this has failed to translate into gains for investors. In fact, if you have owned shares in this producer of hydrogen fuel cell systems for power generation over the past year, you are

It wasn’t very long ago when QuantumScape (NYSE:QS) stock was flying high. The party didn’t last long, however, and some of QuantumScape’s investors are seeing red on their screens now. Unfortunately, I expect the shares to lose more value in the coming weeks. It may be discourteous to call electric vehicle battery technology specialist QuantumScape a

Tesla (NASDAQ:TSLA) stock gets more and more complex by the year, as does the rest of the electric vehicle market. Despite its remarkable growth, investors have much to anticipate in the coming years. In 2022, EVs represented under 10% of total U.S. car sales, leaving substantial growth potential, with 48% of Q1 2023 revenue from

WeWork (NYSE:WE), a workspace leasing company, was a buzz worthy “unicorn” startup business in 2021. That was a while ago, but WE stock still rallies sharply sometimes. Take a closer look at WeWork, however, and you’ll see why financial traders should be wary of this volatile stock. Even if a company looks like it might go

If you are a public equities investor betting on the digital economy, semiconductor stocks would have to be in your portfolio. Semiconductors are tiny electronic devices powering everything from our smartphones and personal computers to cars and commercial airplanes. If you take any run-of-the-mill semiconductor exchange-traded fund (ETF), say, the iShares Semiconductor ETF (NASDAQ:SOXX), many

I’ll start by noting that I’m by no means a critic of the cryptocurrency market in general – although some cryptos I believe investors should sell. The promise of decentralizing authority connected to finance and money is as appealing to me as it’s ever been. The more one learns about traditional finance the more apparent

Adam Aron, the CEO of global movie-theater chain AMC Entertainment (NYSE:AMC), cited the new Barbie movie in the company’s latest quarterly earnings report. I suppose we should have expected Aron to be enthused about Barbie‘s success. But will it be enough to bring AMC stock back to its former glory? Not likely. AMC Entertainment’s second-quarter results weren’t

There’s been plenty of talk about a recession that hasn’t arrived. Although the recession talks have been around for a few years, you can only kick that can down the road so far before it comes full circle. The macroeconomic atmosphere is, to put it bluntly, horrible. Student loan payments will resume in September during

It has been a rough past couple of years for Tilray Brands (NASDAQ:TLRY), but more recently, things have started to look up for TLRY stock. Last month, shares in the Canada-based cannabis company began to rally again, on the heels of a well-received quarterly earnings release. Last week, shares spiked in price yet again, except

Investors seeking defensive exposure in this market may turn their attention to mining socks. These companies, involved in locating, extracting, and processing valuable minerals vital for global industries, play an essential role as a growth engine for the global economy. Without various important base metals, entire industries wouldn’t be possible. Indeed, these companies may be

I’m no more certain than the next speculator regarding the fate of bank stocks in 2023. We’re all aware that this year has been a tough one for the sector. The bank runs a few months back were a scary sight to behold. Thankfully, the banking sector has held up, and things are normal again. However, August

Investors who’ve dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher than with most sectors. Failure is incredibly common for firms that engage in the development of pharmaceuticals. High costs and long product development timelines combine to produce spectacular failures rates, pretty

This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here. 2023 has been an incredible year for the stock market. The Nasdaq Composite has risen 34% so far, its best showing since 1983. The macro picture is looking bright, with inflation on the retreat

Meme stocks have had an eventful summer, with many popular shares seeing sharp rallies. While enthusiasm may not be back to peak 2021 levels, interest is certainly up. Not all meme stocks are set to prosper, though. In fact, many of the worst meme stocks out there continue to have poor fundamentals and even cloudy

By no means is this discussion about meme stocks to sell an indication that you should avoid the sector altogether. Sometimes, it’s good to just have fun (responsibly, of course) in the market. Ultimately, you never know if that wild contrarian wager might turn into something substantive. That, of course, is the main temptation of

With pharmaceutical companies, it’s all about the pipeline of new medications. Drugmakers, and their pharma stocks, are judged based on sales of current medications and potential sales of future prescriptions. Analysts and investors alike are always on the lookout for the next blockbuster drug. This helps to explain why the stocks of pharmaceutical companies with

It’s the height of summer vacation season, and the stock market is taking a breather after its major rally earlier in the year. For active traders, much of the excitement has moved to penny stocks, with many low-priced equities making huge moves in recent weeks. Investors should avoid the urge to go plunging too aggressively

For a hot minute, Wall Street loved electric vehicle (EV) battery technology company QuantumScape (NYSE:QS). Then, financial traders turned against the company and QS stock quickly coughed up its gains. Frankly, it’s just too risky to invest in QuantumScape now. Don’t get the wrong idea. The investing community is fickle, and any stock is susceptible

Chimerix (NASDAQ:CMRX), like most clinical-stage biotech stocks, is without question a high-risk play. Yet in contrast to other biotechs, where high potential rewards can outweigh this high risk, that is not necessarily the case here with CMRX stock. Sure, on paper, Chimerix’s future prospects appear very promising. Last year, the company sold a treatment that

The U.S. equity valuations continue their remarkable trend upward, well beyond anyone’s expectations in 2023. The major indices appreciated amid expectations of a soft landing for the economy as the Federal Reserve battles inflation. While inflation still sits above the Federal Reserve’s target, it is well below where it was 12 months ago. However, despite